An update on current HIV treatments
DOI:
https://doi.org/10.54097/krqrys96Keywords:
Human Immunodeficiency Virus (HIV), HIV life cycle, HIV antiretroviral therapies (ART), HIV treatments, Broadly Neutralizing Antibodies (bNAb).Abstract
The roll-out of antiretroviral therapies (ART) has greatly assisted in reducing the morbidity and mortality rates caused by HIV. However, ART is incapable of eliminating the latent Human Immunodeficiency Virus (HIV), leading to life-long treatment being undertaken. Current HIV cures can be classified into the sterilizing cure, where the HIV latent reservoir is fully eliminated, or the functional cure, where prolonged suppression of latent HIV is achieved. Broadly Neutralizing Antibody (bNAb) is a type of sterilizing cure which targets an epitope on HIV Envelope (Env) protein. Studies indicated that a combined bNAb regiment is better than bNAb monotherapy due to the ability to avoid HIV escape variants. Another type of sterilizing cure is known as “shock and kill” strategy, comprising a latency-reversing agent which activates latent HIV and eliminates it with a “kill” agent. Alternatively, functional cure such as the “Block and lock” strategy utilizes a latency-promoting agent to “block” viral transcription and prevent it from being activated for a prolonged period. Further research and clinical tests are required to develop an HIV cure.
Downloads
References
S. G. Deeks, J. Overbaugh, A. Phillips, and S. Buchbinder, “HIV infection,” Nat Rev Dis Primers, vol. 1, Oct. (2015).
“Global HIV & AIDS statistics — Fact sheet | UNAIDS.” Accessed: Aug. 28, 2023. [Online]. Available: https://www.unaids.org/en/resources/fact-sheet?_gl=1*r6i9d6*_ga*MTI4NjQ5Njc1OC4xNjkzMjMwMTQw*_ga_T7FBEZEXNC*MTY5MzIzMDEzOS4xLjEuMTY5MzIzMDIwOS42MC4wLjA.
T. Tipoe, S. Fidler, and J. Frater, “An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect,” Curr Opin HIV AIDS, vol. 17, no. 3, pp. 162 – 170, May (2022).
C. B. Wilen, J. C. Tilton, and R. W. Doms, “HIV: cell binding and entry,” Cold Spring Harb Perspect Med, vol. 2, no. 8, (2012).
E. O. Freed, “HIV-1 assembly, release and maturation,” Nat Rev Microbiol, vol. 13, no. 8, pp. 484 – 496, Jul. (2015).
E. Dejesus et al., “Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment,” AIDS Res Hum Retroviruses, vol. 34, no. 4, pp. 337 – 342, Apr. (2018).
S. K. Gupta et al., “Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials,” AIDS, vol. 33, no. 9, pp. 1455 – 1465, Jul. (2019).
J. Gallant et al., “Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial,” Lancet, vol. 390, no. 10107, pp. 2063 – 2072, Nov. (2017).
O. O. Agbaji et al., “Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults,” J Int Assoc Provid AIDS Care, vol. 18, Jan. (2019).
A. Cozzi-Lepri et al., “Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing,” J Antimicrob Chemother, vol. 70, no. 3, pp. 930 – 940, Mar. (2015).
J. Gregson et al., “Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study,” Lancet Infect Dis, vol. 16, no. 5, pp. 565 – 575, May (2016).
S. Fidler et al., “Slower CD4 cell decline following cessation of a 3-month course of HAART in primary HIV infection: findings from an observational cohort,” AIDS, vol. 21, no. 10, pp. 1283 – 1291, Jun. (2007).
T. J. Henrich et al., “HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study,” PLoS Med, vol. 14, no. 11, Nov. (2017).
J. F. Scheid et al., “HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption,” Nature, vol. 535, no. 7613, pp. 556 – 560, Jul. (2016).
Y. Bar-On et al., “Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals,” Nat Med, vol. 24, no. 11, pp. 1701 – 1707, Nov. (2018).
N. M. Archin et al., “Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy,” Nature, vol. 487, no. 7408, pp. 482 – 485, Jul. (2012).
T. A. Rasmussen et al., “Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial,” Lancet HIV, vol. 1, no. 1, pp. e13 – e21, (2014).
S. Natesampillai et al., “HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome,” J Virol, vol. 92, no. 13, Jul. (2018).
N. W. Cummins et al., “Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo,” EClinicalMedicine, vol. 42, Dec. (2021).
C. F. Kessing et al., “In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a ‘Block-and-Lock’ Strategy for HIV-1 Treatment,” Cell Rep, vol. 21, no. 3, pp. 600 – 611, Oct. (2017).
G. Mousseau, C. F. Kessing, R. Fromentin, L. Trautmann, N. Chomont, and S. T. Valente, “The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency,” mBio, vol. 6, no. 4, Jul. (2015).
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
